imiquimod has been researched along with Experimental Neoplasms in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, X; Li, X; Liu, L; Wang, Y; Wei, X; Zhao, J; Zhou, S | 1 |
| Culbert, A; Jiang, X; Kaufmann, M; Lin, W; Luo, T; Ni, K | 1 |
| Ferguson, D; Griffith, TS; Khanna, V; Kim, H; Larson, P; Panyam, J; Shah, M; Zhang, W | 1 |
| Du, J; Feng, X; Gao, X; Liu, C; Liu, N; Liu, Z; Lu, D; Qin, S; Wang, Y; Yang, Z; Zhang, T; Zhao, Y; Zhou, H; Zhu, H | 1 |
| Fan, F; Huang, C; Ji, W; Kong, D; Leng, X; Lu, L; Qin, Y; Sun, H; Wang, C; Wu, S; Zhang, L; Zhang, Z; Zhu, D | 1 |
| Broomfield, S; Cleaver, AL; Connor, T; Currie, AJ; Fahmi Alatas, M; Fisher, SA; Khong, A; Lake, RA; Lesterhuis, WJ; Robinson, BW; Wylie, BC | 1 |
| Ando, T; Arioka, Y; Ito, H; Ogiso, H; Seishima, M | 1 |
| Chuang, CM; Hung, CF; Monie, A; Wu, TC | 1 |
| McLaughlin, PJ; Stucki, JK; Zagon, IS | 1 |
| Bhardwaj, N; Jiménez-Baranda, S; Silva, IP | 1 |
| Amberg, N; Colonna, M; Drobits, B; Grundtner, R; Hammer, M; Holcmann, M; Sibilia, M; Swiecki, M | 1 |
| Borden, EC; Bryan, GT; Hatcher, JF; Reiter, MJ; Sidky, YA; Weeks, CE | 1 |
12 other study(ies) available for imiquimod and Experimental Neoplasms
| Article | Year |
|---|---|
Selectively targeting tumor-associated macrophages and tumor cells with polymeric micelles for enhanced cancer chemo-immunotherapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Delayed-Action Preparations; Doxorubicin; Drug Carriers; Drug Therapy, Combination; Female; Humans; Imiquimod; Immunologic Factors; Immunotherapy; Macrophages; Mice; Mice, Inbred BALB C; Micelles; Neoplasms, Experimental; Polyesters; Polyethylene Glycols; Polymers; Toll-Like Receptor 7; Tumor Microenvironment | 2019 |
Nanoscale Metal-Organic Framework Co-delivers TLR-7 Agonists and Anti-CD47 Antibodies to Modulate Macrophages and Orchestrate Cancer Immunotherapy.
Topics: Animals; Antibodies; CD47 Antigen; Cell Line, Tumor; Colorectal Neoplasms; Imiquimod; Immunity, Innate; Immunotherapy; Macrophages; Metal-Organic Frameworks; Mice; Nanostructures; Neoplasms, Experimental; Toll-Like Receptor 7 | 2020 |
Novel TLR 7/8 agonists for improving NK cell mediated antibody-dependent cellular cytotoxicity (ADCC).
Topics: A549 Cells; Animals; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents, Immunological; CD8-Positive T-Lymphocytes; Humans; Imiquimod; Killer Cells, Natural; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Toll-Like Receptor 7; Toll-Like Receptor 8; Xenograft Model Antitumor Assays | 2021 |
ICAM-1 orchestrates the abscopal effect of tumor radiotherapy.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Biomarkers; CD8-Positive T-Lymphocytes; Drug Evaluation, Preclinical; Imiquimod; Intercellular Adhesion Molecule-1; Lymphocytes, Tumor-Infiltrating; Mice, Inbred BALB C; Nanoparticles; Neoplasms, Experimental; Positron-Emission Tomography | 2021 |
Targeted Codelivery of an Antigen and Dual Agonists by Hybrid Nanoparticles for Enhanced Cancer Immunotherapy.
Topics: Animals; Antigens, Neoplasm; Cancer Vaccines; CD8-Positive T-Lymphocytes; Dendritic Cells; Drug Delivery Systems; Imiquimod; Immunotherapy; Lipid A; Mice; Nanoparticles; Neoplasms, Experimental; Toll-Like Receptors | 2019 |
The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Antibodies, Monoclonal; CD40 Antigens; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cytoreduction Surgical Procedures; Drug Administration Schedule; Female; Imiquimod; Immunotherapy; Membrane Glycoproteins; Mesothelioma; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Toll-Like Receptor 7; Treatment Outcome | 2014 |
Inhibition of induced nitric oxide synthase enhances the anti-tumor effects on cancer immunotherapy using TLR7 agonist in mice.
Topics: Aminoquinolines; Animals; Antineoplastic Agents; Cytokines; Female; Flow Cytometry; Imiquimod; Immunotherapy; Interferon-gamma; Lymphocytes, Tumor-Infiltrating; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Neoplasms, Experimental; Nitric Oxide Synthase Type II; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Toll-Like Receptor 7; Tumor Cells, Cultured | 2015 |
Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Calreticulin; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Female; Human papillomavirus 16; Humans; Imiquimod; Killer Cells, Natural; Macrophages; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Papillomavirus E7 Proteins; Papillomavirus Vaccines; T-Lymphocytes, Regulatory; Toll-Like Receptor 7; Vaccines, DNA | 2010 |
Modulation of the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: novel therapies for squamous cell carcinoma of the head and neck.
Topics: Aminoquinolines; Analysis of Variance; Animals; Carcinoma, Squamous Cell; Disease Models, Animal; DNA; Dose-Response Relationship, Drug; Drug Administration Schedule; Head and Neck Neoplasms; Humans; Imiquimod; Injections, Intraperitoneal; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Receptors, Opioid; Reference Values; Squamous Cell Carcinoma of Head and Neck; Transplantation, Heterologous; Treatment Outcome; Tumor Burden; Up-Regulation | 2012 |
Plasmacytoid dendritic cells lead the charge against tumors.
Topics: Adaptive Immunity; Adjuvants, Immunologic; Aminoquinolines; Animals; Antineoplastic Agents; Dendritic Cells; Humans; Imiquimod; Neoplasms, Experimental | 2012 |
Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells.
Topics: Adaptive Immunity; Adjuvants, Immunologic; Aminoquinolines; Animals; Antineoplastic Agents; Cell Line, Tumor; Chemokine CCL2; Dendritic Cells; Humans; Imiquimod; Melanoma; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Mice, Knockout; Myeloid Differentiation Factor 88; Neoplasms, Experimental; Receptor, Interferon alpha-beta; Signal Transduction; Skin; Toll-Like Receptor 7 | 2012 |
Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine.
Topics: Aminoquinolines; Animals; Cyclophosphamide; Female; Imiquimod; Immune Sera; Interferon Inducers; Interferons; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Neoplasms, Experimental; Rabbits; Tumor Necrosis Factor-alpha | 1992 |